IMC Share Price

Open 0.32 Change Price %
High 0.32 1 Day 0.00 0.00
Low 0.32 1 Week 0.02 6.67
Close 0.32 1 Month 0.00 0.00
Volume 187832 1 Year -0.14 -30.43
52 Week High 0.52
52 Week Low 0.22
IMC Important Levels
Resistance 2 0.32
Resistance 1 0.32
Pivot 0.32
Support 1 0.32
Support 2 0.32
ASX Australia Most Active Stocks
AKK 0.01 0.00%
GPP 0.03 0.00%
IMU 0.01 0.00%
IMU 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
DUE 2.74 16.60%
DUE 2.74 16.60%
PDN 0.06 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AHN 0.04 100.00%
AZS 0.03 50.00%
AZS 0.03 50.00%
PMQ 0.03 50.00%
NGY 0.05 25.00%
BIT 0.05 25.00%
BIT 0.05 25.00%
RAW 0.06 20.00%
RAW 0.06 20.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
BMN 0.02 -33.33%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
NMS 0.90 -23.73%
More..

Immuron Ltd (ASX: IMC)

IMC Technical Analysis 1.5
As on 5th Dec 2016 IMC Share Price closed @ 0.32 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.34 & Buy for SHORT-TERM with Stoploss of 0.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
IMC Target for December
1st Target up-side 0.37
2nd Target up-side 0.4
3rd Target up-side 0.42
1st Target down-side 0.31
2nd Target down-side 0.28
3rd Target down-side 0.26
IMC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.immuron.com
IMC Address
IMC
1233 High Street
Suite 1
Armadale, VIC 3143
Australia
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
IMC Latest News
Interactive Technical Analysis Chart Immuron Ltd ( IMC ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Immuron Ltd
IMC Business Profile
Immuron Limited, a biopharmaceutical company, is engaged in the research and development, and sale of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company’s platform technology enables the development of medicines that target a range of medical needs, including infectious diseases, immune mediated disorders, and cancers. It commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. The company offers Travelan, a natural product for the prevention of Travellers’ Diarrhoea. It is also developing IMM 272, a bovine colostrum powder to prevent rotavirus diarrhea; IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/type 2 diabetes; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Armadale, Australia.